# Marc-Henri Stern

## List of Publications by Year in Descending Order



| | | | |
|---|---|---|---|
| 114 papers | 5,738 citations | 42 h-index | 74 g-index |
| 132 ext. papers | 6,827 ext. citations | 8 avg, IF | 5.05 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 114 | Chromosome 3 and 8q aberrations in Uveal Melanoma show greater impact on survival in patients with light iris versus dark iris color. *Ophthalmology*, **2021**, | 7.3 | 5 |
| 113 | Splicing Patterns in -Mutated Uveal Melanoma Generate Shared Immunogenic Tumor-Specific Neoepitopes. *Cancer Discovery*, **2021**, 11, 1938-1951 | 24.4 | 9 |
| 112 | A DNA methylation-based liquid biopsy for triple-negative breast cancer. *Npj Precision Oncology*, **2021**, 5, 53 | 9.8 | 4 |
| 111 | Definition of Biologically Distinct Groups of Conjunctival Melanomas According to Etiological Factors and Implications for Precision Medicine. *Cancers*, **2021**, 13, | 6.6 | 3 |
| 110 | Germline MBD4 Mutations and Predisposition to Uveal Melanoma. *Journal of the National Cancer Institute*, **2021**, 113, 80-87 | 9.7 | 20 |
| 109 | Genetic alterations of SUGP1 mimic mutant-SF3B1 splice pattern in lung adenocarcinoma and other cancers. *Oncogene*, **2021**, 40, 85-96 | 9.2 | 3 |
| 108 | Functional and conformational impact of cancer-associated mutations depends on the position and the charge of amino acid substitution. *Computational and Structural Biotechnology Journal*, **2021**, 19, 1361-1370 | 6.8 | 1 |
| 107 | Ultraviolet radiation drives mutations in a subset of mucosal melanomas. *Nature Communications*, **2021**, 12, 259 | 17.4 | 10 |
| 106 | High-Accuracy Determination of Microsatellite Instability Compatible with Liquid Biopsies. *Clinical Chemistry*, **2020**, 66, 606-613 | 5.5 | 16 |
| 105 | Reinstated p53 response and high anti-T-cell leukemia activity by the novel alkylating deacetylase inhibitor tinostamustine. *Leukemia*, **2020**, 34, 2513-2518 | 10.7 | 6 |
| 104 | BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers. *Science Translational Medicine*, **2020**, 12, | 17.5 | 43 |
| 103 | A single droplet digital PCR for ESR1 activating mutations detection in plasma. *Oncogene*, **2020**, 39, 2987-2995 | 7.2 | 16 |
| 102 | Clinical Interest of Combining Transcriptomic and Genomic Signatures in High-Grade Serous Ovarian Cancer. *Frontiers in Genetics*, **2020**, 11, 219 | 4.5 | 8 |
| 101 | Lack of evidence for CDK12 as an ovarian cancer predisposing gene. *Familial Cancer*, **2020**, 19, 203-209 | 3 | 1 |
| 100 | Uveal melanoma. *Nature Reviews Disease Primers*, **2020**, 6, 24 | 51.1 | 143 |
| 99 | DNA repair functional analyses of NBN hypomorphic variants associated with NBN-related infertility. *Human Mutation*, **2020**, 41, 608-618 | 4.7 | 3 |
| 98 | ShallowHRD: detection of homologous recombination deficiency from shallow whole genome sequencing. *Bioinformatics*, **2020**, 36, 3888-3889 | 7.2 | 2 |

| | | | |
|---|---|---|---|
| 97 | ART-DeCo: easy tool for detection and characterization of cross-contamination of DNA samples in diagnostic next-generation sequencing analysis. *European Journal of Human Genetics*, **2019**, 27, 792-800 | 5.3 | 7 |
| 96 | Evolutionary Routes in Metastatic Uveal Melanomas Depend on Alterations. *Clinical Cancer Research*, **2019**, 25, 5513-5524 | 12.9 | 31 |
| 95 | Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer: A Prospective Ancillary Study to the Unicancer Prodige-14 Trial. *Cells*, **2019**, 8, | 7.9 | 40 |
| 94 | Functional classification of ATM variants in ataxia-telangiectasia patients. *Human Mutation*, **2019**, 40, 1713-1730 | 4.7 | 17 |
| 93 | Three new cases of ataxia-telangiectasia-like disorder: No impairment of the ATM pathway, but S-phase checkpoint defect. *Human Mutation*, **2019**, 40, 1690-1699 | 4.7 | 11 |
| 92 | JAK/STAT-Activating Genomic Alterations Are a Hallmark of T-PLL. *Cancers*, **2019**, 11, | 6.6 | 14 |
| 91 | Prospective validation in epithelial tumors of a gene expression predictor of liver metastasis derived from uveal melanoma. *Scientific Reports*, **2019**, 9, 17178 | 4.9 | 2 |
| 90 | Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL. *Nature Communications*, **2018**, 9, 697 | 17.4 | 51 |
| 89 | Location of Mutation in Gene and Survival in Patients with Ovarian Cancer. *Clinical Cancer Research*, **2018**, 24, 326-333 | 12.9 | 28 |
| 88 | Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy. *Nature Reviews Clinical Oncology*, **2018**, 15, 639-650 | 19.4 | 108 |
| 87 | Medullary Breast Carcinoma, a Triple-Negative Breast Cancer Associated with BCLG Overexpression. *American Journal of Pathology*, **2018**, 188, 2378-2391 | 5.8 | 6 |
| 86 | Multiple Hotspot Mutations Scanning by Single Droplet Digital PCR. *Clinical Chemistry*, **2018**, 64, 317-328 | 5.5 | 28 |
| 85 | Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling. *Leukemia*, **2018**, 32, 774-787 | 10.7 | 56 |
| 84 | Outlier response to anti-PD1 in uveal melanoma reveals germline MBD4 mutations in hypermutated tumors. *Nature Communications*, **2018**, 9, 1866 | 17.4 | 65 |
| 83 | Patient-Specific Circulating Tumor DNA Detection during Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. *Clinical Chemistry*, **2017**, 63, 691-699 | 5.5 | 104 |
| 82 | Micronuclei Frequency in Tumors Is a Predictive Biomarker for Genetic Instability and Sensitivity to the DNA Repair Inhibitor AsiDNA. *Cancer Research*, **2017**, 77, 4207-4216 | 10.1 | 20 |
| 81 | Modulating BAP1 expression affects ROS homeostasis, cell motility and mitochondrial function. *Oncotarget*, **2017**, 8, 72513-72527 | 3.3 | 20 |
| 80 | Contribution of germline deleterious variants in the RAD51 paralogs to breast and ovarian cancers. *European Journal of Human Genetics*, **2017**, 25, 1345-1353 | 5.3 | 21 |

| | | | |
|---|---|---|---|
| 79 | ATM Gene Mutation Detection Techniques and Functional Analysis. *Methods in Molecular Biology*, **2017**, 1599, 25-42 | 1.4 | |
| 78 | Breast and ovarian cancer predisposition due to de novo BRCA1 and BRCA2 mutations. *Oncogene*, **2016**, 35, 1324-7 | 9.2 | 25 |
| 77 | Ovarian Cancers Harboring Inactivating Mutations in CDK12 Display a Distinct Genomic Instability Pattern Characterized by Large Tandem Duplications. *Cancer Research*, **2016**, 76, 1882-91 | 10.1 | 66 |
| 76 | Circulating tumor DNA for triple-negative breast cancer diagnosis and treatment decisions. *Expert Review of Molecular Diagnostics*, **2016**, 16, 39-50 | 3.8 | 9 |
| 75 | Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer. *Molecular Oncology*, **2016**, 10, 481-93 | 7.9 | 61 |
| 74 | Gene Expression and Alternative Splicing Datasets Analyses of MDS with Ring Sideroblasts Highlight Alternative Branchpoint Usage in Genes Involved in Iron Metabolism and Erythropoiesis. *Blood*, **2016**, 128, 1972-1972 | 2.2 | |
| 73 | Genomic hallmarks of homologous recombination deficiency in invasive breast carcinomas. *International Journal of Cancer*, **2016**, 138, 891-900 | 7.5 | 34 |
| 72 | Genetic landscape of uveal melanoma. *Journal Francais DrOphtalmologie*, **2015**, 38, 522-5 | 0.8 | 6 |
| 71 | Metaplastic breast carcinomas display genomic and transcriptomic heterogeneity [corrected].. *Modern Pathology*, **2015**, 28, 340-51 | 9.8 | 56 |
| 70 | Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients. *International Journal of Cancer*, **2015**, 136, 2158-65 | 7.5 | 115 |
| 69 | The inactive X chromosome is epigenetically unstable and transcriptionally labile in breast cancer. *Genome Research*, **2015**, 25, 488-503 | 9.7 | 81 |
| 68 | Upcoming translational challenges for uveal melanoma. *British Journal of Cancer*, **2015**, 113, 1249-53 | 8.7 | 16 |
| 67 | Histo-genomic stratification reveals the frequent amplification/overexpression of CCNE1 and BRD4 genes in non-BRCAness high grade ovarian carcinoma. *International Journal of Cancer*, **2015**, 137, 1890-900 | 7.5 | 29 |
| 66 | Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types. *Molecular Oncology*, **2015**, 9, 783-90 | 7.9 | 200 |
| 65 | First description of a sporadic breast cancer in a woman with BRCA1 germline mutation. *Oncotarget* , **2015**, 6, 35616-24 | 3.3 | 7 |
| 64 | Subgroups of T-Cell Prolymphocytic Leukemia (T-PLL) Discovered By High-Throughput Ex Vivo Drug Testing and Genetic Profiling. *Blood*, **2015**, 126, 315-315 | 2.2 | |
| 63 | A common alternative splicing signature is associated with SF3B1 mutations in malignancies from different cell lineages. *Leukemia*, **2014**, 28, 1355-7 | 10.7 | 24 |
| 62 | Recurrent JAK1 and JAK3 somatic mutations in T-cell prolymphocytic leukemia. *Leukemia*, **2014**, 28, 417-9 | 10.7 | 70 |

| | | | |
|---|---|---|---|
| 61 | The pleiotropic movement disorders phenotype of adult ataxia-telangiectasia. *Neurology*, **2014**, 83, 1087-95 | 6.5 | 54 |
| 60 | Polarity gene alterations in pure invasive micropapillary carcinomas of the breast. *Breast Cancer Research*, **2014**, 16, R46 | 8.3 | 30 |
| 59 | Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma. *International Journal of Cancer*, **2014**, 134, 1207-13 | 7.5 | 129 |
| 58 | Streamlined ion torrent PGM-based diagnostics: BRCA1 and BRCA2 genes as a model. *European Journal of Human Genetics*, **2014**, 22, 535-41 | 5.3 | 51 |
| 57 | Germline mutation in the RAD51B gene confers predisposition to breast cancer. *BMC Cancer*, **2013**, 13, 484 | 4.8 | 49 |
| 56 | Germline BAP1 mutations predispose to renal cell carcinomas. *American Journal of Human Genetics*, **2013**, 92, 974-80 | 11 | 188 |
| 55 | Genomic amplification is not a frequent event in uveal melanomas. *American Journal of Pathology*, **2013**, 183, 638 | 5.8 | |
| 54 | Patient-derived xenografts recapitulate molecular features of human uveal melanomas. *Molecular Oncology*, **2013**, 7, 625-36 | 7.9 | 37 |
| 53 | SF3B1 mutations are associated with alternative splicing in uveal melanoma. *Cancer Discovery*, **2013**, 3, 1122-1129 | 24.4 | 282 |
| 52 | MiR-30a-5p connects EWS-FLI1 and CD99, two major therapeutic targets in Ewing tumor. *Oncogene*, **2013**, 32, 3915-21 | 9.2 | 60 |
| 51 | Loss of heterozygosity at 13q13 and 14q32 predicts BRCA2 inactivation in luminal breast carcinomas. *International Journal of Cancer*, **2013**, 133, 2834-42 | 7.5 | 6 |
| 50 | Mutation in TTI2 reveals a role for triple T complex in human brain development. *Human Mutation*, **2013**, 34, 1472-6 | 4.7 | 18 |
| 49 | STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model. *Haematologica*, **2013**, 98, 1748-52 | 6.6 | 40 |
| 48 | Circulating tumor DNA (ctDNA) in metastatic uveal melanoma (MUM): Correlation with outcome in 87 patients (pts) from Institut Curie. *Acta Ophthalmologica*, **2013**, 91, 0-0 | 3.7 | 0 |
| 47 | Designs and challenges for personalized medicine studies in oncology: focus on the SHIVA trial. *Targeted Oncology*, **2012**, 7, 253-65 | 5 | 44 |
| 46 | Breast and ovarian cancer risk management in a French cohort of 158 women carrying a BRCA1 or BRCA2 germline mutation: patient choices and outcome. *Familial Cancer*, **2012**, 11, 473-82 | 3 | 11 |
| 45 | A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -positive breast cancers. *Journal of Pathology*, **2012**, 227, 29-41 | 9.4 | 44 |
| 44 | Pyrophosphorolysis-activated polymerization detects circulating tumor DNA in metastatic uveal melanoma. *Clinical Cancer Research*, **2012**, 18, 3934-41 | 12.9 | 63 |

| | | | |
|---|---|---|---|
| 43 | Underexpression and abnormal localization of ATM products in ataxia telangiectasia patients bearing ATM missense mutations. *European Journal of Human Genetics*, **2012**, 20, 305-12 | 5.3 | 28 |
| 42 | Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. *Cancer Research*, **2012**, 72, 5454-62 | 10.1 | 340 |
| 41 | Syntenic relationships between genomic profiles of fiber-induced murine and human malignant mesothelioma. *American Journal of Pathology*, **2011**, 178, 881-94 | 5.8 | 44 |
| 40 | TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. *Cancer Cell*, **2011**, 20, 25-38 | 24.3 | 653 |
| 39 | TET2 Inactivation Results in Pleiotropic Hematopoietic Abnormalities in Mouse and Is a Recurrent Event during Human Lymphomagenesis. *Cancer Cell*, **2011**, 20, 276 | 24.3 | 2 |
| 38 | Leukemic phase of follicular lymphomas: an atypical presentation. *Leukemia and Lymphoma*, **2011**, 52, 1504-8 | 1.9 | 12 |
| 37 | Oxidative stress promotes myofibroblast differentiation and tumour spreading. *EMBO Molecular Medicine*, **2010**, 2, 211-30 | 12 | 200 |
| 36 | Proteomic analysis of BRCA1-depleted cell line reveals a putative role for replication protein A2 up-regulation in BRCA1 breast tumor development. *Proteomics - Clinical Applications*, **2010**, 4, 489-98 | 3.1 | 2 |
| 35 | Molecular allelokaryotyping of T-cell prolymphocytic leukemia cells with high density single nucleotide polymorphism arrays identifies novel common genomic lesions and acquired uniparental disomy. *Haematologica*, **2009**, 94, 518-27 | 6.6 | 21 |
| 34 | The TCL1A oncoprotein interacts directly with the NF-kappaB inhibitor IkappaB. *PLoS ONE*, **2009**, 4, e6567 | 4.7 | 10 |
| 33 | High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors. *Cancer Research*, **2009**, 69, 663-71 | 10.1 | 119 |
| 32 | Fertility defects revealing germline biallelic nonsense NBN mutations. *Human Mutation*, **2009**, 30, 424-30 | 4.7 | 14 |
| 31 | Genome Alteration Print (GAP): a tool to visualize and mine complex cancer genomic profiles obtained by SNP arrays. *Genome Biology*, **2009**, 10, R128 | 18.3 | 150 |
| 30 | Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells. *Breast Cancer Research*, **2008**, 10, R101 | 8.3 | 168 |
| 29 | Haploinsufficiency of CDKN1B contributes to leukemogenesis in T-cell prolymphocytic leukemia. *Blood*, **2008**, 111, 2321-8 | 2.2 | 43 |
| 28 | Genetic heterogeneity versus molecular analysis of prion susceptibility in neuroblasma N2a sublines. *Archives of Virology*, **2008**, 153, 1693-702 | 2.6 | 9 |
| 27 | The MTCP1 oncogene modifies T-cell homeostasis before leukemogenesis in transgenic mice. *Leukemia*, **2007**, 21, 362-6 | 10.7 | 9 |
| 26 | JUN oncogene amplification and overexpression block adipocytic differentiation in highly aggressive sarcomas. *Cancer Cell*, **2007**, 11, 361-74 | 24.3 | 146 |

| | | | |
|---|---|---|---|
| 25 | X inactive-specific transcript RNA coating and genetic instability of the X chromosome in BRCA1 breast tumors. *Cancer Research*, **2007**, 67, 5134-40 | 10.1 | 74 |
| 24 | Pre-TCR expression cooperates with TEL-JAK2 to transform immature thymocytes and induce T-cell leukemia. *Blood*, **2007**, 109, 3972-81 | 2.2 | 27 |
| 23 | The TCL1 oncoprotein inhibits activation-induced cell death by impairing PKCtheta and ERK pathways. *Blood*, **2007**, 110, 4406-16 | 2.2 | 17 |
| 22 | VAMP: visualization and analysis of array-CGH, transcriptome and other molecular profiles. *Bioinformatics*, **2006**, 22, 2066-73 | 7.2 | 104 |
| 21 | Re: Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas. *Journal of the National Cancer Institute*, **2006**, 98, 365-6 | 9.7 | 43 |
| 20 | Structural basis for the co-activation of protein kinase B by T-cell leukemia-1 (TCL1) family proto-oncoproteins. *Journal of Biological Chemistry*, **2004**, 279, 35890-902 | 5.4 | 40 |
| 19 | Solution structure and backbone dynamics of the pleckstrin homology domain of the human protein kinase B (PKB/Akt). Interaction with inositol phosphates. *Journal of Biomolecular NMR*, **2004**, 28, 137-55 | 3 | 42 |
| 18 | In vitro and in vivo effectiveness of arsenic trioxide against murine T-cell prolymphocytic leukaemia. *British Journal of Haematology*, **2002**, 117, 343-50 | 4.5 | 11 |
| 17 | Identification of Akt association and oligomerization domains of the Akt kinase coactivator TCL1. *Molecular and Cellular Biology*, **2002**, 22, 1513-25 | 4.8 | 82 |
| 16 | A complex pattern of recurrent chromosomal losses and gains in T-cell prolymphocytic leukemia. *Genes Chromosomes and Cancer*, **2001**, 31, 248-54 | 5 | 76 |
| 15 | Molecular analysis of the mature T cell proliferation-1 (MTCP-1) gene in Xq28-linked incontinentia pigmenti. *European Journal of Human Genetics*, **2000**, 8, 239-40 | 5.3 | |
| 14 | Backbone dynamics and solution structure refinement of the 15N-labeled human oncogenic protein p13MTCP1: comparison with X-ray data. *Journal of Biomolecular NMR*, **2000**, 17, 215-30 | 3 | 20 |
| 13 | Recurrent molecular deletion of the 12p13 region, centromeric to ETV6/TEL, in T-cell prolymphocytic leukemia. *The Hematology Journal*, **2000**, 1, 42-7 | | 19 |
| 12 | Refined solution structure and backbone dynamics of 15N-labeled C12A-p8MTCP1 studied by NMR relaxation. *Journal of Biomolecular NMR*, **1999**, 15, 271-88 | 3 | 32 |
| 11 | TCL1 oncogene expression in AIDS-related lymphomas and lymphoid tissues. *Proceedings of the National Academy of Sciences of the United States of America*, **1999**, 96, 9809-14 | 11.5 | 73 |
| 10 | Solution structure of the recombinant human oncoprotein p13MTCP1. *Journal of Biomolecular NMR* , **1998**, 11, 337-54 | 3 | 10 |
| 9 | Crystal structure of p14TCL1, an oncogene product involved in T-cell prolymphocytic leukemia, reveals a novel beta-barrel topology. *Structure*, **1998**, 6, 147-55 | 5.2 | 42 |
| 8 | Solution structure of human p8MTCP1, a cysteine-rich protein encoded by the MTCP1 oncogene, reveals a new alpha-helical assembly motif. *Journal of Molecular Biology*, **1997**, 274, 801-15 | 6.5 | 23 |

| | | | |
|---|---|---|---|
| 7 | Alternative origin of p13MTCP1-encoding transcripts in mature T-cell proliferations with t(X;14) translocations. *Oncogene*, **1997**, 15, 1329-35 | 9.2 | 7 |
| 6 | Hybrid T cell receptor genes formed by interlocus recombination in normal and ataxia-telangiectasis lymphocytes. *Journal of Experimental Medicine*, **1990**, 172, 409-18 | 16.6 | 108 |
| 5 | Mapping of human chromosome 22 by in situ hybridization. *Genomics*, **1990**, 7, 319-24 | 4.3 | 17 |
| 4 | Molecular characterization of ataxia telangiectasia T cell clones. III. Mapping the 14q32.1 distal breakpoint. *Human Genetics*, **1988**, 81, 18-22 | 6.3 | 9 |
| 3 | Molecular characterization of different ataxia telangiectasia T-cell clones. I. A common breakpoint at the 14q11.2 band splits the T-cell receptor alpha-chain gene. *Human Genetics*, **1988**, 78, 33-6 | 6.3 | 22 |
| 2 | Molecular characterization of ataxia telangiectasia T cell clones. II. The clonal inv(14) in ataxia telangiectasia differs from the inv(14) in T cell lymphoma. *Human Genetics*, **1988**, 78, 316-9 | 6.3 | 11 |
| 1 | Functional subdivision of HLA-DRw8 with influenza-specific cloned cell lines. *Immunogenetics*, **1985**, 22, 407-12 | 3.2 | 8 |